← Metformin × all-cause mortality

Observational studyAnnals of internal medicine2015

Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.

Shuo-Ming Ou et al.PubMed ↗Publisher ↗

What the trial testedrandomised · 2015

Randomised comparison

Probably reduced deaths

−37%−45% to −28%

Bigger than 8 in 10 for all-cause mortality

As reported

HR 0.63, 95% CI 0.55–0.72 · the paper's word: All-cause mortality

Randomised comparison

Probably reduced deaths

−32%−45% to −17%

Bigger than 8 in 10 for all-cause mortality

As reported

HR 0.68, 95% CI 0.55–0.83 · the paper's word: All-cause mortality

Randomised comparison

Probably reduced deaths

−36%−49% to −19%

Bigger than 8 in 10 for all-cause mortality

As reported

HR 0.64, 95% CI 0.51–0.81 · the paper's word: All-cause mortality

Randomised comparison

Probably reduced deaths

−57%−67% to −44%

Bigger than 9 in 10 for all-cause mortality

As reported

HR 0.43, 95% CI 0.33–0.56 · the paper's word: All-cause mortality

Four numbers in the abstract

the abstract, start to end

… for all-cause death (hazard ratio [HR], 0.63 [95% CI, 0.55 to 0.72]), MACEs (HR, 0.68 [CI, 0.55 to 0.83]), ischemic stroke (HR, 0.64 [CI, 0.51 to 0.81]), and hypoglycemia (HR, 0.43 [CI, 0.33 to 0.56]) compared …

← favours treatmentfavours comparator →
could be chance
All-cause mortality
HR 0.630.55–0.72
All-cause mortality
HR 0.680.55–0.83
All-cause mortality
HR 0.640.51–0.81
All-cause mortality
HR 0.430.33–0.56
MetforminSulfonylureas & glinidesAll-cause mortality
1 / 3

53 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 26457538